Literature DB >> 3584859

Abnormal daily periodicity of serum thyrotropin (TSH) and evidence for defective TSH suppression in a case of non-neoplastic syndrome of inappropriate TSH secretion.

S Benvenga, G A Sobbrio, F Vermiglio, L Li Calzi, S Cannavò, F Consolo, F Trimarchi.   

Abstract

A non-neoplastic syndrome of inappropriate secretion of TSH (ITSHS) was diagnosed in a hemithyroidectomized and clinically euthyroid 44-yr-old man, who also exhibited limping (Perthes' disease), genu valgum, pes supinatus and lateral nystagmus. Computed tomography demonstrated an enlarged sella turcica due to empty sella. Baseline serum T3, T4, free T3, free T4 and TSH fluctuated between 179 and 274 ng/dl, 6.0 and 13.2 micrograms/dl, 4.2 and 6.0 pg/ml, 7.6 and 15.3 pg/ml, and 4.3 and 33.0 microU/ml, respectively. Serum alpha-TSH subunit was repeatedly normal (0.36-0.69 ng/ml) over the follow-up period (greater than 3 yr). No changes in serum liver enzymes and lipids were observed after thyroid hormone administration, whereas red blood cell glucose-6-phosphate dehydrogenase (G-6-PD) and urinary OH-proline were slightly enhanced during 120 micrograms/day L-T3 regimen. This also resulted in an inappropriately normal glucagon-stimulated cAMP levels. Tachycardia was experienced only during L-T3 and very high L-T4 dose treatments. Therefore, the patient showed some evidence for thyroid hormone peripheral refractoriness. Patient's TSH was physiologically responsive to agents (thyrotropin releasing hormone, methimazole, the dopamine antagonists domperidone and sulpiride) known to elicit its release into circulation, while it responded paradoxically to those which normally inhibit TSH secretion. In fact, the infusion of somatostatin (320 micrograms/h) or dopamine (4 micrograms/Kg/min), and the oral administration of bromocriptine or nomifensine (two dopamine agonists) or corticosteroids (dexamethasone) provoked an unexpected elevation of both unstimulated and TRH-stimulated TSH levels.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3584859     DOI: 10.1007/BF03347191

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  30 in total

1.  Defective thyroid hormone feedback regulation in the syndrome of peripheral resistance to thyroid hormone.

Authors:  S Refetoff; L J Degroot; C P Barsano
Journal:  J Clin Endocrinol Metab       Date:  1980-07       Impact factor: 5.958

2.  Familial partial peripheral resistance to thyroid hormones.

Authors:  B A Lamberg; S Rosengård; K Liewendahl; P Saarinen; D C Evered
Journal:  Acta Endocrinol (Copenh)       Date:  1978-02

3.  Nomifensine: a new potent inhibitor of dopamine uptake into synaptosomes from rat brain corpus striatum.

Authors:  P Hunt; M Kannengiesser; J Raynaud
Journal:  J Pharm Pharmacol       Date:  1974-05       Impact factor: 3.765

4.  Thyrotropin-induced hyperthyroidism caused by selective pituitary resistance to thyroid hormone. A new syndrome of "inappropriate secretion of TSH".

Authors:  M C Gershengorn; B D Weintraub
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

5.  The effect of somatostatin on TSH levels in patients with primary hypothyroidism.

Authors:  C Lucke; B Höffken; A von zur Mühlen
Journal:  J Clin Endocrinol Metab       Date:  1975-12       Impact factor: 5.958

6.  Successful treatment of hyperthyroidism due to nonneoplastic pituitary TSH hypersecretion with 3,5,3'-triiodothyroacetic acid (TRIAC).

Authors:  P Beck-Peccoz; G Piscitelli; M G Cattaneo; G Faglia
Journal:  J Endocrinol Invest       Date:  1983-06       Impact factor: 4.256

Review 7.  Syndromes of thyroid hormone resistance.

Authors:  S Refetoff
Journal:  Am J Physiol       Date:  1982-08

8.  Resistance to thyroid hormones. A disorder frequently confused with Graves' disease.

Authors:  J P Bantle; S Seeling; C N Mariash; R A Ulstrom; J H Oppenheimer
Journal:  Arch Intern Med       Date:  1982-10

9.  Familial hyperthyroidism due to inappropriate thyrotropin secretion successfully treated with triiodothyronine.

Authors:  A Rösler; Y Litvin; C Hage; J Gross; E Cerasi
Journal:  J Clin Endocrinol Metab       Date:  1982-01       Impact factor: 5.958

10.  The effect of glucocorticoids on thyrotropin secretion.

Authors:  J F Wilber; R D Utiger
Journal:  J Clin Invest       Date:  1969-11       Impact factor: 14.808

View more
  1 in total

1.  Increased levothyroxine requirements presenting as "inappropriate" TSH secretion syndrome in a patient with nephrotic syndrome.

Authors:  M T Collins; A T Remaley; G Csako; F Pucino; M C Skarulis; J E Balow; N J Sarlis
Journal:  J Endocrinol Invest       Date:  2000-06       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.